Fuzhou Tuoxin Tiancheng Biotechnology

Tcelltech’s core business revolves around the research, development, and production of cell-based therapeutic technologies. The company's main product, TX-103, is an autologous CAR-T cell therapy that targets B7-H3, a protein found on various solid tumors. TX-103 has shown promising results in treating recurrent glioblastoma (rGBM), one of the most aggressive types of brain cancer. Clinical trials have indicated that TX-103 can significantly extend the survival of rGBM patients, who otherwise have a very poor prognosis. The therapy has received clinical trial approvals in both China and the United States and is currently undergoing multi-center international trials.

The company's business model is centered on the entire drug development process, from initial research and development to clinical-grade production, quality management, and clinical studies. Tcelltech serves biomedical research institutions and healthcare providers. The company has successfully raised significant capital to advance its clinical programs, including a Series B financing round of nearly $40 million in July 2025. This funding is being used to advance the clinical development of TX-103, support the research of other pipeline products, and expand the company's team and international presence.